Merck EBITDA Margin 2010-2024 | MKKGY
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Merck (MKKGY) over the last 10 years. The current EBITDA margin for Merck as of June 30, 2024 is .
| Merck EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-06-30 |
$22.58B |
$5.84B |
25.85% |
| 2024-03-31 |
$22.60B |
$5.85B |
25.87% |
| 2023-12-31 |
$22.72B |
$5.94B |
26.15% |
| 2023-09-30 |
$22.91B |
$6.34B |
27.65% |
| 2023-06-30 |
$23.13B |
$6.45B |
27.91% |
| 2023-03-31 |
$23.27B |
$6.65B |
28.59% |
| 2022-12-31 |
$23.42B |
$6.85B |
29.26% |
| 2022-09-30 |
$23.58B |
$7.01B |
29.70% |
| 2022-06-30 |
$23.60B |
$7.08B |
30.01% |
| 2022-03-31 |
$23.54B |
$7.06B |
29.98% |
| 2021-12-31 |
$23.29B |
$7.03B |
30.17% |
| 2021-09-30 |
$22.79B |
$6.52B |
28.61% |
| 2021-06-30 |
$22.12B |
$6.74B |
30.46% |
| 2021-03-31 |
$20.79B |
$6.13B |
29.47% |
| 2020-12-31 |
$20.03B |
$5.62B |
28.07% |
| 2020-09-30 |
$19.42B |
$5.58B |
28.74% |
| 2020-06-30 |
$18.73B |
$4.81B |
25.66% |
| 2020-03-31 |
$18.66B |
$4.85B |
25.99% |
| 2019-12-31 |
$18.09B |
$4.55B |
25.16% |
| 2019-09-30 |
$17.42B |
$4.34B |
24.88% |
| 2019-06-30 |
$17.27B |
$4.19B |
24.28% |
| 2019-03-31 |
$17.24B |
$3.98B |
23.10% |
| 2018-12-31 |
$17.52B |
$4.18B |
23.85% |
| 2018-09-30 |
$17.87B |
$4.02B |
22.46% |
| 2018-06-30 |
$17.90B |
$4.59B |
25.63% |
| 2018-03-31 |
$17.75B |
$4.72B |
26.61% |
| 2017-12-31 |
$17.32B |
$4.84B |
27.94% |
| 2017-09-30 |
$16.90B |
$5.05B |
29.85% |
| 2017-06-30 |
$16.68B |
$4.66B |
27.93% |
| 2017-03-31 |
$16.70B |
$4.76B |
28.48% |
| 2016-12-31 |
$16.63B |
$4.89B |
29.40% |
| 2016-09-30 |
$16.29B |
$4.75B |
29.13% |
| 2016-06-30 |
$15.63B |
$4.54B |
29.08% |
| 2016-03-31 |
$14.89B |
$4.25B |
28.54% |
| 2015-12-31 |
$14.31B |
$3.78B |
26.39% |
| 2015-09-30 |
$13.91B |
$3.51B |
25.23% |
| 2015-06-30 |
$14.32B |
$3.50B |
24.42% |
| 2015-03-31 |
$14.59B |
$3.52B |
24.15% |
| 2014-12-31 |
$14.78B |
$3.64B |
24.62% |
| 2014-09-30 |
$15.11B |
$4.17B |
27.62% |
| 2014-06-30 |
$14.86B |
$4.42B |
29.77% |
| 2014-03-31 |
$14.80B |
$4.76B |
32.19% |
| 2013-12-31 |
$14.72B |
$4.82B |
32.72% |
| 2013-09-30 |
$14.64B |
$7.31B |
49.91% |
| 2013-06-30 |
$14.55B |
$6.65B |
45.70% |
| 2013-03-31 |
$14.30B |
$5.44B |
38.02% |
| 2012-12-31 |
$14.00B |
$7.60B |
54.31% |
| 2012-09-30 |
$13.66B |
$7.27B |
53.18% |
| 2012-06-30 |
$13.69B |
$10.25B |
74.86% |
| 2012-03-31 |
$13.85B |
$10.32B |
74.54% |
| 2011-12-31 |
$14.08B |
$10.55B |
74.95% |
| 2011-09-30 |
$14.47B |
$10.95B |
75.64% |
| 2011-06-30 |
$14.03B |
$7.98B |
56.87% |
| 2011-03-31 |
$13.05B |
$10.53B |
80.64% |
| 2010-12-31 |
$12.34B |
$9.81B |
79.52% |
| 2010-09-30 |
$11.61B |
$9.09B |
78.24% |
| 2010-06-30 |
$11.25B |
$11.25B |
100.00% |
| 2010-03-31 |
$11.14B |
$11.14B |
100.00% |
| 2009-12-31 |
$10.81B |
$10.81B |
100.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$21.306B |
$22.719B |
|
Merck is a global pharmaceutical and chemical company. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
|
